MRCT held a webinar this week (May 2 nd ) on RETURNING INDIVIDUAL RESEARCH RESULTS AND DATA TO PARTICIPANTS: EXPERIENCE FROM THE FIELDThey worked with partners to create a series of case studies. These cases detailthe...
On 21 March 2023, in Basel, Switzerland, the TransCelerate project co-hosted a workshop with EFPIA - European Federation of Pharmaceutical Industries and Associations to collaborate on modernizing clinical trials and...
On 15 and 16 March, the leaders of work package 3 (WP3) held a meeting with partners at Eurac Research, Bolzano (Italy). The meeting was convened to discuss key elements of the ethical frameworks (the ethical framework...
On 1 March 2023, Prof. Dr. Johanna Blom has been invited to present FACILITATE project and its challenges at the 3rd International Conference on Rare Diseases: Greek Chapter, 2023, Athens in the Session “Flash Updates...
Year 2/Issue 1 February 2023 We have just entered the second year of FACILITATE, and are ready to face the new challenges that the project poses and to work together to realize our goals. Collaboration,...
On 23 February 2023, the development of guidelines for the return of clinical trial data has been discussed at the 14th International Congress on Human Genetics in Cape Town The return of individual research results is...
On 21 February 2023, representatives of WP3 held a FACILITATE stakeholder workshop at Stellenbosch Medical School, Cape Town, South Africa The workshop was hosted jointly with the Stellenbosch University Research...
VUB discusses the EHDS proposal with the LIBE committee of the European Parliament On 9 January 2023, the Health and Aging Law Lab (HALL) at Vrije Universiteit Brussel (VUB), WP2 (legal) leader of the FACILITATE...
In accordance with resolutions 75/282 and 76/552 of the UN’s General Assembly, FACILITATE partner Privanova joined the expert panel of the Ad Hoc Committee tasked with drafting a Comprehensive International Convention...
The current fragmentation of clinical data in separate repositories, and the partition of the data protection laws, among other reasons, make the return and re-use of clinical trial data particularly complex and...
